Cysteine proteinase type II (CPB)

Leishmania Cysteine proteinase type II is a critical enzyme belonging to the papain-like (C1) family of cysteine proteases, essential for the survival and pathogenesis of Leishmania species [3, 7]. Depending on the species and literature convention, this term is used to refer to either Cysteine protease B (CPB) or Cysteine protease A (CPA), both of which are cathepsin L-like enzymes [12, 13, 20]. The enzyme is primarily localized in the lysosomal megasomes of the amastigote stage, where it functions in the degradation of host proteins for nutrient acquisition and the processing of parasite proteins [1, 6]. It also plays a significant role in immune evasion by degrading host MHC class II molecules, thereby preventing effective antigen presentation and T-cell activation [7, 13]. As a major virulence factor, its genetic deletion or pharmacological inhibition leads to impaired parasite replication and reduced infectivity in mammalian hosts [5, 24]. Consequently, it is a prominent target for the development of novel antileishmanial drugs and vaccines [17, 23]. Various experimental inhibitors, including vinyl sulfones like K777 and peptidomimetic nitriles, have shown efficacy in blocking the enzyme's active site, though achieving selectivity over human cathepsins remains a key therapeutic challenge [5, 9].

Other names

Cysteine protease BCysteine protease ACPBCPACathepsin L-like cysteine proteaseCysteine proteinase 2Amastigote cysteine proteinase A-2

Inhibition of the catalytic cysteine residue in the active site, preventing the hydrolysis of peptide bonds essential for parasite growth and virulence [5, 7].